1374 related articles for article (PubMed ID: 27118452)
21. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
22. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
23. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Enblad G; Karlsson H; Gammelgård G; Wenthe J; Lövgren T; Amini RM; Wikstrom KI; Essand M; Savoldo B; Hallböök H; Höglund M; Dotti G; Brenner MK; Hagberg H; Loskog A
Clin Cancer Res; 2018 Dec; 24(24):6185-6194. PubMed ID: 30097433
[TBL] [Abstract][Full Text] [Related]
25. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
[TBL] [Abstract][Full Text] [Related]
26. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
[TBL] [Abstract][Full Text] [Related]
27. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
28. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
[TBL] [Abstract][Full Text] [Related]
30. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
31. Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Aldoss I; Khaled SK; Wang X; Palmer J; Wang Y; Wagner JR; Clark MC; Simpson J; Paul J; Vyas V; Chien SH; Stein A; Pullarkat V; Salhotra A; Al Malki MM; Aribi A; Sandhu K; Thomas SH; Budde LE; Marcucci G; Brown CE; Forman SJ
Clin Cancer Res; 2023 Feb; 29(4):742-753. PubMed ID: 36255386
[TBL] [Abstract][Full Text] [Related]
32. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
34. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
35. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
[No Abstract] [Full Text] [Related]
36. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
37. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
38. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
Savoldo B; Ramos CA; Liu E; Mims MP; Keating MJ; Carrum G; Kamble RT; Bollard CM; Gee AP; Mei Z; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Dotti G
J Clin Invest; 2011 May; 121(5):1822-6. PubMed ID: 21540550
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
